Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study

Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events (AEs) are still scarce. Methods. We conducted a retrospective cohort study including all patients who were prescr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzitelli, Maria, Mengato, Daniele, Sasset, Lolita, Ferrari, Anna, Gardin, Samuele, Scaglione, Vincenzo, Bonadiman, Nicola, Calandrino, Lucrezia, Cavinato, Silvia, Trivellato, Sabrina, Venturini, Francesca, Cattelan, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962206/
https://www.ncbi.nlm.nih.gov/pubmed/36851598
http://dx.doi.org/10.3390/v15020384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962206/
https://www.ncbi.nlm.nih.gov/pubmed/36851598
http://dx.doi.org/10.3390/v15020384

Ejemplares similares